Cargando…

Advances in PSMA theranostics

The validation of prostate specific membrane antigen (PSMA) as a molecular target in metastatic castration-resistant prostate cancer has stimulated the development of multiple classes of theranostic ligands that specifically target PSMA. Theranostic ligands are used to image disease or selectively d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeitner, Thomas M., Babich, John W., Kelly, James M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123266/ https://www.ncbi.nlm.nih.gov/pubmed/35597190 http://dx.doi.org/10.1016/j.tranon.2022.101450

Ejemplares similares

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
por: Bychkov, Andrey, et al.
Publicado: (2017)

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
por: Flores, Orielyz, et al.
Publicado: (2017)

PSMA Theranostics: Current Landscape and Future Outlook
por: Zhang, Hanbo, et al.
Publicado: (2021)

The Magnetic Appeal of Silencing Theranostics
por: Bulte, Jeff W.M.
Publicado: (2012)

The current status of prostate cancer treatment and PSMA theranostics
por: Uemura, Motohide, et al.
Publicado: (2023)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

Theranostics on the immunoactivity of T cells
por: Shi, Changrong, et al.
Publicado: (2023)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

Spotlight on PSMA as a new theranostic biomarker for bladder cancer
por: Tumedei, Maria Maddalena, et al.
Publicado: (2021)

Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R
por: Schollhammer, Romain, et al.
Publicado: (2023)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

PSMA as a target for radiolabelled small molecules
por: Eder, Matthias, et al.
Publicado: (2013)

Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
por: Derks, Yvonne H. W., et al.
Publicado: (2023)

PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
por: Debnath, Sashi, et al.
Publicado: (2022)

Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer
por: Derks, Yvonne H. W., et al.
Publicado: (2022)

Decoding of exosome heterogeneity for cancer theranostics
por: Dhar, Rajib, et al.
Publicado: (2023)

Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective
por: Ng, Thomas S. C., et al.
Publicado: (2021)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?
por: Lauri, Chiara, et al.
Publicado: (2022)

A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers
por: Aide, Nicolas, et al.
Publicado: (2021)

Bibliometric Analysis of Theranostics: Two Years in the Making
por: Ho, Don N., et al.
Publicado: (2013)

Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors
por: Lütje, Susanne, et al.
Publicado: (2019)

Vesicular drug-delivery systems as theranostics in COVID-19
por: Satija, Saurabh, et al.
Publicado: (2020)

Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast
por: Vranic, Semir, et al.
Publicado: (2018)

The potential of engineered multifunctional quantum dots for macrophage theranostics
por: Yin, Chengliang, et al.
Publicado: (2023)

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
por: Lückerath, Katharina, et al.
Publicado: (2018)

Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review
por: Gauthé, Mathieu, et al.
Publicado: (2021)

Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles
por: Daldrup-Link, Heike E.
Publicado: (2017)

PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches
por: Bui, Vinh Ngoc, et al.
Publicado: (2023)

Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial
por: Martinez, Juana, et al.
Publicado: (2022)

Synthesis and pre-clinical evaluation of a new class of high-affinity (18)F-labeled PSMA ligands for detection of prostate cancer by PET imaging
por: Kelly, James, et al.
Publicado: (2016)

Progress on carbon dots and hydroxyapatite based biocompatible luminescent nanomaterials for cancer theranostics
por: Sengar, Prakhar, et al.
Publicado: (2022)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2019)

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
por: Gaudreault, Mathieu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gli3blktltb0bel9p9fsp1fpf6